Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D) (AWARE-CKD)
Awareness of Diagnosis and Treatment of Chronic Kidney Disease in Patients With Type 2 Diabetes
In this survey study, researchers want to find out more about how physicians are treating patients diagnosed with reduced kidney function (chronic kidney disease, CKD) and high blood sugar level (type 2 diabetes); what physicians know about the different treatment options available; and how they use this knowledge to treat their patients successfully. Additionally, researchers want to gather information about patient's awareness of their disease and which criteria they consider important for their treatment of the disease.
The study will survey a total of 150 patients with type 2 diabetes: 50 patients with mild CKD; 50 patients with moderate CKD; and 50 patients with severe CKD. Patients eligible for this study can be male or female and should be at least 18 years old. In addition, a total of 150 physicians will be surveyed. Physicians eligible for this study may be general practitioners, endocrinologist, or nephrologists.
調査の概要
詳細な説明
The primary objective in this study is to assess the awareness, values and preferences of patients and physicians with respect to the risks, consequences and management of chronic kidney disease (CKD) in patients with type 2 diabetes.
Secondary objectives aim to assess awareness of available CKD treatments, referral tools and communication between patients and physicians.
Both patients and physicians will complete a survey that consists of various questions regarding the knowledge of disease, values and treatments, patient-physician interaction, physician referral tools and disease risk management.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Multiple Locations、カナダ
- Many facilities
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
For patient cohort:
- Diagnosis of type 2 diabetes
- eGFR < 60 ml/min per 1.73 m2 (measured within the last year) OR eGFR ≥ 60 ml/min per 1.73 m2 and uACR ≥ 2 (measured within the last year)
- No documented non-diabetic etiology for renal disease
For physician cohort:
- Licensed general practitioner, endocrinologist or nephrologist
- Currently providing care for patients with chronic kidney disease and type 2 diabetes
Exclusion Criteria:
- Patients with chronic kidney disease and type 2 diabetes who are physicians
- Physicians with chronic kidney disease and type 2 diabetes
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
CKD-Patients
Cohort consisting of adult patients with a known diagnosis of type 2 diabetes and evidence of chronic kidney disease (CKD)
|
無介入、観察研究
|
|
Physicians treating CKD
Cohort consisting of licensed general practitioners, endocrinologists and nephrologists who are currently treating patients with both chronic kidney disease (CKD) and type 2 diabetes
|
無介入、観察研究
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Awareness of chronic kidney disease in T2D
時間枠：1 day
|
Awareness will be summarized descriptively based on various survey questions.
|
1 day
|
|
Values regarding chronic kidney disease in T2D
時間枠：1 day
|
Values regarding risks, consequences and management of chronic kidney disease will be summarized descriptively based on various survey questions.
|
1 day
|
|
Preferences regarding chronic kidney disease in T2D
時間枠：1 day
|
Preferences regarding risks, consequences and management of chronic kidney disease will be summarized descriptively based on various survey questions.
|
1 day
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Awareness of available treatments for chronic kidney disease in T2D
時間枠：1 day
|
Awareness of available treatments will be summarized descriptively based on various survey questions.
|
1 day
|
|
Physician awareness of available referral tools for the management of chronic kidney disease in T2D
時間枠：1 day
|
Physician cohort only.
Referral tools may comprise of various standard guidelines (e.g.
KidneyWise, KDIGO guidelines, Diabetes Canada guidelines).
A higher number of referral tools known by physicians indicates a better awareness of CKD referral tools.
|
1 day
|
|
Time point of communicated CKD diagnosis
時間枠：1 day
|
1 day
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 21225
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
介入なしの臨床試験
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical Center; Tobacco Related Disease Research Program完了
-
University of Southern CaliforniaNational Institutes of Health (NIH)積極的、募集していない
-
University of MichiganNational Institute on Drug Abuse (NIDA)完了
-
University of PittsburghCenters for Disease Control and Prevention募集暴力, ドメスティック | 思春期の暴力 | 暴力、性的 | 暴力、身体的 | 暴力, 偶然ではない | 社会的結束 | 暴力、構造 | コミュニティ内暴力アメリカ